IBM Stock Slips on Slower Software Growth Despite Q2 Beat
Warning! GuruFocus has detected 4 Warning Sign with AMZN.
Projections were off by $16.98 billion in revenue and $2.80 in adjusted profits per share. But the software sales were $7.39 billion, which was a little less than the $7.43 billion that most people expected.
IBM CEO Arvind Krishna claimed that geopolitical concerns and weaker U.S. federal spending were to blame for slower client activity, but he said that long-term expectations had not changed.
UBS analysts reaffirmed their "sell" rating but boosted their price target to $200 because software revenue growth was slowing down. Bank of America lowered its price target from $320 to $310, but kept its "buy" rating. It said that the segment's performance will be a "show me story" for the remainder of 2025.
Wedbush analysts were positive about IBM's position in hybrid cloud and AI and saw the drop after earnings as a possible buying opportunity.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Paracetamol Market size & share revenue was valued at approximately USD 876.48 Million in 2024 and is expected to reach USD 922.41 Million in 2025 and is expected to reach around USD 1460.23 Million by 2034, at a CAGR of 5.24% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Aspen Pharmacare, Adcock Ingram, Julphar (Gulf Pharmaceutical Industries), Ache Laboratories Pharmaceutics, EMS Pharma, Hikma Pharmaceuticals, Bharat Chemicals, Farmson Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Mylan N.V. (now part of Viatris) and others. Austin, TX, USA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Paracetamol Market Size, Trends and Insights By Product Type (Tablet, Capsule, Liquid Suspension, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application Type (Headache & Fever, Muscle Cramps, Cold & Cough), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Paracetamol Market size & share was valued at approximately USD 876.48 Million in 2024 and is expected to reach USD 922.41 Million in 2025 and is expected to reach a value of around USD 1460.23 Million by 2034, at a compound annual growth rate (CAGR) of about 5.24% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Overview As per the industry experts at CMI, the paracetamol market is expected to witness a linear CAGR during the forecast period. This could be attributed to steadiness on the part of demand for paracetamol globally. Paracetamol is being used as an antipyretic and analgesic, especially in fever and pain relief medications. The market is further catalyzed by growing healthcare awareness, increasing incidences of chronic conditions, and a rising aging population worldwide. Key Trends & Drivers Growing Incidences of Fever and Pain to Determine Growth: Ailments such as flu, headaches, arthritis, and post-operative pain are reported to be managed using paracetamol. Rising incidences on their part do directly translate into a higher demand for medication. The consumers are also increasingly developing awareness about OTC medications such as paracetamol and do prefer treating minor illnesses on their own, thereby driving its usage further. Request a Customized Copy of the Paracetamol Market Report @ Increased Usage in Surgical Applications to Catalyze the Paracetamol Market: IV paracetamol is increasingly preferred due to its ability to effectively manage moderate to severe pain without side effects linked with opioids, such as constipation and nausea. It makes provision for quicker pain relief in comparison with oral medications, thereby making it the most sought-after medication post-surgery. Report Scope Feature of the Report Details Market Size in 2025 USD 922.41 Million Projected Market Size in 2034 USD 1460.23 Million Market Size in 2024 USD 876.48 Million CAGR Growth Rate 5.24% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product Type, Distribution Channel, Application Type and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Paracetamol report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Paracetamol report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Paracetamol Market Report @ SWOT Analysis Strengths: Paracetamol is easily accessible OTC in various forms such as capsules, tablets, and liquids. It is comparatively inexpensive, thereby rendering it cost-effective for a wider consumer base. Plus, it is one of the common ingredients in various fever-reducing and pain relief products and is used for treating conditions such as muscle aches, headaches, and the common cold. Rising occurrences of lifestyle-oriented ailments are the catalysts to paracetamol market. Weaknesses: Improper dosage or overuse could cause damage to the liver. Additionally, the reliance of the market on API production in certain regions is likely to create vulnerabilities pertaining to the supply chain. Furthermore, the market is bound to face fierce competition from the manufacturers of generic medicines, which could reduce the market share of established players and reduce their overall profitability. Opportunities: Researching and developing paracetamol-based products for specified pain conditions such as migraines are likely to unlock novel market segments. Also, exploration of the use of paracetamol in conjunction with the other drugs for improved pain relief and the other therapeutic advantages could provide lucrative opportunities to the paracetamol market. Threats: Negative publicity around the safety concerns related to paracetamol is likely to negatively affect the consumers' demand and perception. Also, Volatility of costs of raw materials used in the production of paracetamol could adversely affect profitability and production costs. Emergence of newer combinations of pain management solutions could also cut down on market share. Request a Customized Copy of the Paracetamol Market Report @ Key questions answered in this report: What is the size of the Paracetamol market and what is its expected growth rate? What are the primary driving factors that push the Paracetamol market forward? What are the Paracetamol Industry's top companies? What are the different categories that the Paracetamol Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Paracetamol market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The paracetamol market is divided into North America, Europe, Asia Pacific, and LAMEA. North America North America leads the paracetamol market, and the status quo is expected to remain unchanged during the forecast period. This is credited to rising incidences of migraines, headaches, and fever all across the U.S. The American Migraine Foundation states that the year 2020 witnessed the presence of over 4 million adults in the U.S. battling chronic daily migraine, that too, with close to 15 headaches per month. The government is also handsomely investing in research regarding therapeutics for chronic pain. As per the May 2022 update from the NIH (National Institute of Health), the government of the U.S. did spend USD 689 Million and USD 725 Million in 2020 and 2021 respectively in this regard. Europe Europe is expected to hold a significant share of the paracetamol market owing to an increase in healthcare spending on the part of the governments. The tropical regions are prone to year-round influenza, which is fueling the market therein. The EU has set stringent regulatory standards for various pharmaceuticals (inclusive of paracetamol), which ascertain safety and quality. Asia Pacific Asia Pacific is expected to witness the highest CAGR in the paracetamol market during the forecast period. This could be due to a rise in the population suffering from the common cold, cough, fever, and migraine. China and India are the major manufacturers of paracetamol APIs. They are thus paving the way for cost-effective supply chains. LAMEA Individuals in LAMEA are gaining more awareness regarding the advantages of self-treating the minor ailments with OTC medications such as paracetamol, thereby resulting in a higher rate of consumption. Increase in accessibility of e-Commerce platforms and online pharmacies is making it simpler for the consumers based in LAMEA to buy paracetamol, thereby boosting the market further. Request a Customized Copy of the Paracetamol Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Paracetamol Market Size, Trends and Insights By Product Type (Tablet, Capsule, Liquid Suspension, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application Type (Headache & Fever, Muscle Cramps, Cold & Cough), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Paracetamol Market: Johnson & Johnson GlaxoSmithKline Pfizer Inc. Novartis AG Reddy's Laboratories Ltd. Aspen Pharmacare Adcock Ingram Julphar (Gulf Pharmaceutical Industries) Ache Laboratories Pharmaceutics EMS Pharma Hikma Pharmaceuticals Bharat Chemicals Farmson Pharmaceuticals SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation) Mylan N.V. (now part of Viatris) Others Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: US Surgical Instrument Tracking System Market: US Surgical Instrument Tracking Market Size, Trends and Insights By Technology (Barcodes, RFID), By Application (Hardware, Software, Services), By End-use (Hospitals, Ambulatory Surgical Centers), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Digital Mammography Market: Digital Mammography Market Size, Trends and Insights By Technology (2D Full Field Digital Mammography, 3D Full Field Digital Mammography (Digital Breast Tomosynthesis), Contrast Enhanced Digital Mammography), By Product Type (Digital Mammography System, Display Unit, Central Processing Units, Visualization Software), By End-user (Hospitals and Surgical Centers, Breast Care Centers, Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Lenacapavir Injection Market: Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Pharmaceutical Metal Detector Market: Pharmaceutical Metal Detector Market Size, Trends and Insights By Technology (Magnetic Field Detectors, Multi-frequency Detectors, X-Ray Inspection with Metal Detectors), By Application (Quality Control, Contaminant Detection, Packaging, Compliance), By End-user (Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Biopharmaceutical Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Deep Eutectic Solvents Market: Deep Eutectic Solvents Market Size, Trends and Insights By Product (Organic Salts + Metal Salts, Organic Salts + Metal Hydrates, Organic Salts + Hydrogen Bond Donor, Metal Chlorides + Hydrogen Bond Donor), By End-use (Pharmaceuticals & Healthcare, Food & Beverages Processing, Cosmetics & Personal Care, Chemical & Materials Industry), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Medical Equipment Calibration Services Market: Medical Equipment Calibration Services Market Size, Trends and Insights By Service (In-house, Third-party Services, Original Equipment Manufacturers (OEMs)), By End-use (Hospitals, Clinical Laboratories), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 CRISPR and Cas Genes Market: CRISPR and Cas Genes Market Size, Trends and Insights By Technology Type (CRISPR/Cas9, CRISPR/Cas13, CRISPR/Cas14, Others), By Delivery Method (Ex vivo, In vivo, Physical Methods, Others), By Application Area (Functional Genomics, Oncology, Infectious Diseases, Others), By Tool Type (Guide RNA, CRISPR Plasmids, Cas Nucleases, Custom CRISPR Libraries, Vectors & Cloning Kits), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Industrial Crops), By Disease Type (Cancer, Blood Disorders, Ophthalmic Diseases, Infectious Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Y Chromosome Microdeletion Detection Kit Market: Y Chromosome Microdeletion Detection Kit Market Size, Trends and Insights By Product Type (PCR-based Kits, FISH-based Kits, Others), By Application (Hospitals, Diagnostic Laboratories, Research Institutes, Others), By End-User (Healthcare Providers, Research Laboratories, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Paracetamol Market is segmented as follows: By Product Type Tablet Capsule Liquid Suspension Powder By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Application Type Headache & Fever Muscle Cramps Cold & Cough Click Here to Get a Free Sample Report of the Global Paracetamol Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Paracetamol Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Paracetamol Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Paracetamol Market? What Was the Capacity, Production Value, Cost and PROFIT of the Paracetamol Market? What Is the Current Market Status of the Paracetamol Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Paracetamol Market by Considering Applications and Types? What Are Projections of the Global Paracetamol Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Paracetamol Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Paracetamol Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Paracetamol Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Paracetamol Industry? Click Here to Access a Free Sample Report of the Global Paracetamol Market @ Reasons to Purchase Paracetamol Market Report Paracetamol Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Paracetamol Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Paracetamol Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Paracetamol Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Paracetamol market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Paracetamol market analysis. The competitive environment of current and potential participants in the Paracetamol market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Paracetamol market should find this report useful. The research will be useful to all market participants in the Paracetamol industry. Managers in the Paracetamol sector are interested in publishing up-to-date and projected data about the worldwide Paracetamol market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Paracetamol products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Paracetamol Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Paracetamol Research Report | Fast Delivery Available - [220+ Pages] @ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
28 minutes ago
- Business Wire
UBS AG published its 2Q25 financial report
ZURICH--(BUSINESS WIRE)--Regulatory News: UBS (NYSE:UBS) (SWX:UBSN): Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules UBS AG today published its second-quarter 2025 consolidated financial report. UBS Group AG previously reported its second-quarter results 2025 on a consolidated basis on 30 July 2025. These reports are available for download on the UBS website. Cautionary Statement Regarding Forward-Looking Statements This report contains statements that constitute 'forward-looking statements', including but not limited to management's outlook for UBS's financial performance, statements relating to the anticipated effect of transactions and strategic initiatives on UBS's business and future development and goals or intentions to achieve climate, sustainability and other social objectives. While these forward-looking statements represent UBS's judgments, expectations and objectives concerning the matters described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from UBS's expectations. In particular, the global economy may suffer significant adverse effects from increasing political tensions between world powers, changes to international trade policies, including those related to tariffs and trade barriers, and ongoing conflicts in the Middle East, as well as the continuing Russia–Ukraine war. UBS's acquisition of the Credit Suisse Group has materially changed its outlook and strategic direction and introduced new operational challenges. The integration of the Credit Suisse entities into the UBS structure is expected to continue through 2026 and presents significant operational and execution risk, including the risks that UBS may be unable to achieve the cost reductions and business benefits contemplated by the transaction, that it may incur higher costs to execute the integration of Credit Suisse and that the acquired business may have greater risks or liabilities than expected. Following the failure of Credit Suisse, Switzerland is considering significant changes to its capital, resolution and regulatory regime, which, if adopted, would significantly increase our capital requirements or impose other costs on UBS. These factors create greater uncertainty about forward-looking statements. Other factors that may affect UBS's performance and ability to achieve its plans, outlook and other objectives also include, but are not limited to: (i) the degree to which UBS is successful in the execution of its strategic plans, including its cost reduction and efficiency initiatives and its ability to manage its levels of risk-weighted assets (RWA) and leverage ratio denominator (LRD), liquidity coverage ratio and other financial resources, including changes in RWA assets and liabilities arising from higher market volatility and the size of the combined Group; (ii) the degree to which UBS is successful in implementing changes to its businesses to meet changing market, regulatory and other conditions; (iii) inflation and interest rate volatility in major markets; (iv) developments in the macroeconomic climate and in the markets in which UBS operates or to which it is exposed, including movements in securities prices or liquidity, credit spreads, currency exchange rates, residential and commercial real estate markets, general economic conditions, and changes to national trade policies on the financial position or creditworthiness of UBS's clients and counterparties, as well as on client sentiment and levels of activity; (v) changes in the availability of capital and funding, including any adverse changes in UBS's credit spreads and credit ratings of UBS, as well as availability and cost of funding to meet requirements for debt eligible for total loss-absorbing capacity (TLAC); (vi) changes in central bank policies or the implementation of financial legislation and regulation in Switzerland, the US, the UK, the EU and other financial centers that have imposed, or resulted in, or may do so in the future, more stringent or entity-specific capital, TLAC, leverage ratio, net stable funding ratio, liquidity and funding requirements, heightened operational resilience requirements, incremental tax requirements, additional levies, limitations on permitted activities, constraints on remuneration, constraints on transfers of capital and liquidity and sharing of operational costs across the Group or other measures, and the effect these will or would have on UBS's business activities; (vii) UBS's ability to successfully implement resolvability and related regulatory requirements and the potential need to make further changes to the legal structure or booking model of UBS in response to legal and regulatory requirements including heightened requirements and expectations due to its acquisition of the Credit Suisse Group; (viii) UBS's ability to maintain and improve its systems and controls for complying with sanctions in a timely manner and for the detection and prevention of money laundering to meet evolving regulatory requirements and expectations, in particular in the current geopolitical turmoil; (ix) the uncertainty arising from domestic stresses in certain major economies; (x) changes in UBS's competitive position, including whether differences in regulatory capital and other requirements among the major financial centers adversely affect UBS's ability to compete in certain lines of business; (xi) changes in the standards of conduct applicable to its businesses that may result from new regulations or new enforcement of existing standards, including measures to impose new and enhanced duties when interacting with customers and in the execution and handling of customer transactions; (xii) the liability to which UBS may be exposed, or possible constraints or sanctions that regulatory authorities might impose on UBS, due to litigation, contractual claims and regulatory investigations, including the potential for disqualification from certain businesses, potentially large fines or monetary penalties, or the loss of licenses or privileges as a result of regulatory or other governmental sanctions, as well as the effect that litigation, regulatory and similar matters have on the operational risk component of its RWA; (xiii) UBS's ability to retain and attract the employees necessary to generate revenues and to manage, support and control its businesses, which may be affected by competitive factors; (xiv) changes in accounting or tax standards or policies, and determinations or interpretations affecting the recognition of gain or loss, the valuation of goodwill, the recognition of deferred tax assets and other matters; (xv) UBS's ability to implement new technologies and business methods, including digital services, artificial intelligence and other technologies, and ability to successfully compete with both existing and new financial service providers, some of which may not be regulated to the same extent; (xvi) limitations on the effectiveness of UBS's internal processes for risk management, risk control, measurement and modeling, and of financial models generally; (xvii) the occurrence of operational failures, such as fraud, misconduct, unauthorized trading, financial crime, cyberattacks, data leakage and systems failures, the risk of which is increased with persistently high levels of cyberattack threats; (xviii) restrictions on the ability of UBS Group AG, UBS AG and regulated subsidiaries of UBS AG to make payments or distributions, including due to restrictions on the ability of its subsidiaries to make loans or distributions, directly or indirectly, or, in the case of financial difficulties, due to the exercise by FINMA or the regulators of UBS's operations in other countries of their broad statutory powers in relation to protective measures, restructuring and liquidation proceedings; (xix) the degree to which changes in regulation, capital or legal structure, financial results or other factors may affect UBS's ability to maintain its stated capital return objective; (xx) uncertainty over the scope of actions that may be required by UBS, governments and others for UBS to achieve goals relating to climate, environmental and social matters, as well as the evolving nature of underlying science and industry and the increasing divergence among regulatory regimes; (xxi) the ability of UBS to access capital markets; (xxii) the ability of UBS to successfully recover from a disaster or other business continuity problem due to a hurricane, flood, earthquake, terrorist attack, war, conflict, pandemic, security breach, cyberattack, power loss, telecommunications failure or other natural or man-made event; and (xxiii) the effect that these or other factors or unanticipated events, including media reports and speculations, may have on its reputation and the additional consequences that this may have on its business and performance. The sequence in which the factors above are presented is not indicative of their likelihood of occurrence or the potential magnitude of their consequences. UBS's business and financial performance could be affected by other factors identified in its past and future filings and reports, including those filed with the US Securities and Exchange Commission (the SEC). More detailed information about those factors is set forth in documents furnished by UBS and filings made by UBS with the SEC, including the UBS Group AG and UBS AG Annual Reports on Form 20-F for the year ended 31 December 2024. UBS is not under any obligation to (and expressly disclaims any obligation to) update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Rounding | Numbers presented throughout this report may not add up precisely to the totals provided in the tables and text. Percentages and percent changes disclosed in text and tables are calculated on the basis of unrounded figures. Absolute changes between reporting periods disclosed in the text, which can be derived from numbers presented in related tables, are calculated on a rounded basis. Tables | Within tables, blank fields generally indicate non-applicability or that presentation of any content would not be meaningful, or that information is not available as of the relevant date or for the relevant period. Zero values generally indicate that the respective figure is zero on an actual or rounded basis. Values that are zero on a rounded basis can be either negative or positive on an actual basis. Websites | In this report, any website addresses are provided solely for information and are not intended to be active links. UBS is not incorporating the contents of any such websites into this report.
Bloomberg
29 minutes ago
- Bloomberg
Why Modi Won't Budge on Russian Oil
Narendra Modi strikes a defiant tone in response to Donald Trump's threats over India's Russian oil purchases. Here's why it's a delicate balancing act. (Source: Bloomberg)
